SCHD vs XBI
Schwab US Dividend Equity ETF vs SPDR S&P Biotech ETF
- • SCHD has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • SCHD pays a higher dividend yield (2.95%).
Side-by-side metrics
| Metric | SCHD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.95% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $121.09B | $10.92B |
YTD return | 33.16% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.49 | 1.01 |
P/E ratio | 19.30 | — |
Last price | $35.88 | $156.41 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHD top holdings
| TXN | Texas Instruments Inc | 4.58% |
| COP | ConocoPhillips | 4.35% |
| CVX | Chevron Corp | 4.31% |
| PG | Procter & Gamble Co | 4.24% |
| KO | Coca-Cola Co | 4.13% |
| AMGN | Amgen Inc | 4.08% |
| HD | The Home Depot Inc | 4.01% |
| UNH | UnitedHealth Group Inc | 3.95% |
| MRK | Merck & Co Inc | 3.82% |
| PEP | PepsiCo Inc | 3.79% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SCHD
SCHD (Schwab US Dividend Equity ETF) is High-quality US dividend-paying stocks. Managed by Schwab, the fund carries $121.1B in assets under management, an expense ratio of 0.06%, a dividend yield of 2.95%. Its largest holding is Texas Instruments Inc (TXN), which represents 4.6% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 6.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.